Affordable Access

Access to the full text

Current Reality of Treating Advanced Soft Tissue Sarcoma as Illustrated by Case Studies

Authors
  • Broto, Javier Martín
  • Jones, Robin L.
Type
Published Article
Journal
Oncology
Publisher
S. Karger AG
Publication Date
Apr 13, 2021
Volume
99
Issue
Suppl 1
Pages
8–16
Identifiers
DOI: 10.1159/000515366
PMID: 33849013
Source
Karger
Keywords
License
Green
External links

Abstract

In the first-line setting of advanced soft tissue sarcomas (STS), the treatment aim generally drives decision-making. Anthracycline combinations with ifosfamide or dacarbazine are more appropriate when the aim is tumour shrinkage, and doxorubicin monotherapy is suitable for tumour control. In patients who progress on anthracycline-based regimens, scope exists for tumour shrinkage with trabectedin and concurrent low-dose radiotherapy. Selecting systemic treatment for patients with advanced STS unsuited to receive standard anthracycline-based therapy often involves complex decision-making as clinical trial evidence comparing alternative options is lacking. Key factors to consider are patient characteristics (e.g., age, medical history, performance status), disease characteristics (e.g., stage, histology), and treatment requirements such as the drug’s safety profile, evidence of efficacy by subtype, and approved indication as an alternative first-line treatment option. Real-world data for elderly STS patients derived from retrospective studies and post hoc analyses of clinical trials have particular value in guiding treatment selection and improving the management of this populous but undertreated segment of the STS population.

Report this publication

Statistics

Seen <100 times